Pharmaceutical Regulatory Environment in Europe

The pharmaceutical regulatory environment in Europe is based on a coordinated framework involving the European Union (EU), the European Medicines Agency (EMA), the European Commission and national competent authorities in EU Member States. This regulatory network supports the development, authorisation, manufacture and safety monitoring of medicinal products while maintaining standards for quality, safety and efficacy.

European Medicines Agency

The European Medicines Agency (EMA) plays a central scientific and coordinating role within the European medicines regulatory network.

For human medicines, EMA coordinates scientific evaluation through its scientific committees, provides scientific advice, supports pharmacovigilance and contributes to regulatory activities throughout the medicine lifecycle.

EMA works together with national competent authorities and the European Commission rather than functioning as the sole pharmaceutical regulator for Europe.

European Medicines Regulatory Network

The European medicines regulatory network brings together EMA, national competent authorities in EU and European Economic Area countries, and the European Commission.

This network enables Member States to share scientific expertise and cooperate in areas such as:

• Evaluation of medicinal products
• Clinical trials
• Pharmacovigilance
• Inspections
• Manufacturing oversight
• Regulatory guidance
• Post-authorisation activities

The network supports consistent regulatory standards while allowing responsibilities to be distributed among European and national authorities.

Marketing Authorisation

A medicinal product generally requires a valid marketing authorisation before it can be placed on the EU market.

Depending on the product and applicable legislation, authorisation may involve:

• Centralised procedure
• Decentralised procedure
• Mutual-recognition procedure
• National procedure

Under the centralised procedure, EMA coordinates the scientific evaluation and the European Commission grants the legally binding EU-wide marketing authorisation.

Other procedures involve national competent authorities according to the applicable regulatory pathway.

Clinical Trials Regulation

Clinical trials of medicinal products in the EU/EEA are governed by Regulation (EU) No 536/2014, known as the Clinical Trials Regulation (CTR).

The CTR became applicable on 31 January 2022 and replaced the previous Clinical Trials Directive framework following a transition period.

Since 31 January 2025, ongoing clinical trials in the EU/EEA are required to operate under the CTR framework.

The Regulation is intended to harmonise clinical trial submission, assessment and supervision while maintaining participant protection and transparency.

Current information on the CTR and its implementation is available from the European Medicines Agency’s Clinical Trials Regulation guidance.

Clinical Trials Information System

The Clinical Trials Information System (CTIS) is the central electronic system supporting clinical trial applications and regulatory interactions under the CTR.

Sponsors use CTIS to submit clinical trial applications and manage relevant trial information.

EU/EEA Member States use CTIS to collaboratively assess applications and perform their regulatory responsibilities.

EMA maintains CTIS, while authorisation and oversight of clinical trials remain responsibilities of the Member States.

CTIS also supports greater public transparency regarding clinical trials conducted in the EU/EEA.

For more information about the development of the EU clinical-trial framework, see EU Clinical Trials Regulation and Regulatory Framework.

Ethics Review and Participant Protection

Clinical trials require appropriate ethical review in accordance with the CTR and applicable national arrangements.

The assessment process addresses the protection of participants, informed consent, scientific and ethical considerations and other requirements relevant to conducting the clinical trial.

The interaction between national competent authorities and ethics committees is organised according to the CTR and Member State requirements.

Good Clinical Practice

Clinical trials should be conducted according to Good Clinical Practice (GCP), applicable EU legislation and relevant ethical principles.

GCP supports protection of trial participants and the generation of reliable clinical trial results.

Sponsors, investigators and other parties involved in clinical research have responsibilities for ensuring that trial activities comply with applicable requirements.

Pharmacovigilance

Pharmacovigilance is a major component of the European regulatory system.

Marketing authorisation holders are required to maintain appropriate pharmacovigilance systems and evaluate safety information throughout the lifecycle of authorised medicinal products.

EMA and national competent authorities cooperate in activities such as:

• Adverse reaction monitoring
• Signal management
• Periodic safety reporting
• Risk-management activities
• Safety communications
• Regulatory action when necessary

The EU Good Pharmacovigilance Practices (GVP) framework provides guidance for many pharmacovigilance activities.

Good Manufacturing Practice

Medicinal products and investigational medicinal products are subject to applicable Good Manufacturing Practice (GMP) requirements.

GMP requirements address areas such as:

• Pharmaceutical quality systems
• Personnel
• Premises and equipment
• Documentation
• Production
• Quality control
• Outsourced activities
• Complaints and recalls
• Self-inspection

Regulatory authorities conduct inspections to assess compliance with applicable GMP requirements.

Labelling and Product Information

Authorised medicinal products must have appropriate product information.

Depending on the product and authorisation, this may include:

• Summary of Product Characteristics
• Package leaflet
• Labelling information

Product information should accurately communicate approved indications, dosing, contraindications, warnings, adverse reactions and other information necessary for appropriate use.

Medical Devices and In Vitro Diagnostic Devices

Medical devices and in vitro diagnostic medical devices are governed by regulatory frameworks separate from the medicinal-product legislation.

The principal frameworks include:

• Medical Device Regulation (EU) 2017/745
• In Vitro Diagnostic Medical Device Regulation (EU) 2017/746

These regulations establish requirements relating to safety, performance, conformity assessment, clinical evidence, post-market activities and other aspects of device regulation.

Pricing and Reimbursement

Marketing authorisation and reimbursement are separate processes.

Pricing and reimbursement decisions are primarily made at national level, and requirements vary among European countries.

Companies may therefore need to address national health-technology assessment, pricing and reimbursement requirements after or alongside the regulatory authorisation process.

Regulatory Harmonisation and Cooperation

The European regulatory system combines EU-level legislation and coordination with responsibilities performed by national authorities.

Common regulatory procedures, shared scientific assessments, CTIS, pharmacovigilance cooperation and inspection networks help promote consistent standards across the EU/EEA.

At the same time, certain responsibilities—including aspects of clinical trial assessment, healthcare delivery, pricing and reimbursement—remain with individual countries.

Importance of the Pharmaceutical Regulatory Environment in Europe

The pharmaceutical regulatory environment in Europe covers the complete medicinal-product lifecycle, from clinical development and manufacturing through marketing authorisation and post-authorisation safety monitoring.

Understanding the respective roles of EMA, the European Commission, national competent authorities and ethics committees is essential because regulatory responsibilities are distributed across the European medicines regulatory network rather than concentrated in a single authority.

The implementation of the Clinical Trials Regulation and CTIS represents a major modernization of the European clinical-trial framework and provides a harmonised system for clinical trial applications, assessment and transparency across the EU/EEA.

You may be interested in the programs below: